Insiders who reported open-market trades in the last 12 months at the companies Cameron Turtle files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Cameron Turtle is a corporate insider, tracked as Chief Executive Officer, Director of Spyre Therapeutics, Inc. (SYRE). InsiderAlpha holds 12 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Cameron Turtle submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Cameron Turtle been buying or selling stock?
Recorded transactions: 0 open-market purchases and 37 open-market sales ($10.91M) across all tracked filings.
Cameron Turtle is Chief Executive Officer, Director of Spyre Therapeutics, Inc. (SYRE). 12 SEC Form 4 filings on record going back to 2025, most recently on 3 October 2026. Most recent open-market trade: sold $9K of SYRE on 3 October 2026. Lifetime open-market sales: $10.91M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Cameron Turtle.
InsiderAlpha's records for Cameron Turtle go back to 2025: 12 primary Form 4 filings, an average of 6.0 per year. 37 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
